1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Indomethacin |
| brand | String | Indocin (oral, IV, suppository), Tivorbex (low-dose), Indo-Lemmon |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID • potent non-selective)]] • [[:Category:Analgesics|Analgesic]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' |
| starting_dose | String | Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses |
| preparations | String | Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) |
| fda_max | String | 200 mg/day (typical adult oral) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • rectal • intravenous (PDA closure only) |
| onset | String | 30-60 minutes (oral); rapid relief in acute gout |
| duration | String | 4-6 hours (IR); 24 hours (ER) |
| halflife | String | 4-5 hours'"`UNIQ--ref-00000026-QINU`"' |
| bioavailability | String | ~100% (oral)'"`UNIQ--ref-00000027-QINU`"' |
| pregnancy | String | Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
